QUARTERLY REVIEW

Capital Appreciation Fund

As of March 31, 2024

PORTFOLIO HIGHLIGHTS

The portfolio underperformed the all-equity S&P 500 Index for the three-month period ended March 31, 2024.

Relative performance drivers:

- Stock selection in health care detracted from relative results.
- The utilities sector also weighed due to stock choices.
- Stock selection in the consumer discretionary sector added value.

Additional highlights:

- U.S. stocks soared over the quarter, which created opportunities to trim certain positions on strength. Within fixed income, we added to high yield debt.
- As sentiment has further fueled a risk-on rally that brought major indexes to record highs and diminished the potential upside in stocks, we have taken a more cautious approach. We believe taking a contrarian position, when it is supported by our rigorous fundamental analysis, adds value over time.

FUND INFORMATION

Symbol	PRWCX
CUSIP	77954M105
Inception Date of Fund	June 30, 1986
Benchmark	S&P 500 Index
Expense Information (as of the most recent Prospectus)*	0.74% (Gross) 0.72% (Net)
Fiscal Year End	December 31
12B-1 Fee	–
Total Assets (all share classes)	$60,386,393,886
Percent of Portfolio in Cash	5.0%

*The Fund operates under a contractual expense limitation that expires on April 30, 2024.

PERFORMANCE

(NAV, total return)

			Annualized			
	Three Months	**One Year**	**Three Years**	**Five Years**	**Ten Years**	**Fifteen Years**
Capital Appreciation Fund	5.16%	17.46%	7.81%	11.40%	10.75%	13.32%
S&P 500 Index	10.56	29.88	11.49	15.05	12.96	15.63

CALENDAR YEAR PERFORMANCE

(NAV, total return)

	Inception Date	**2014**	**2015**	**2016**	**2017**	**2018**	**2019**	**2020**	**2021**	**2022**	**2023**
Capital Appreciation Fund	Jun 30 1986	12.25%	5.42%	8.22%	15.38%	0.62%	24.61%	18.16%	18.53%	-11.94%	18.83%
S&P 500 Index		13.69	1.38	11.96	21.83	-4.38	31.49	18.40	28.71	-18.11	26.29

Performance data quoted represents past performance and is not a reliable indicator of future performance. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. To obtain the most recent month-end performance, visit troweprice.com. The Fund's total return figures reflect the reinvestment of dividends and capital gains, if any.

All funds are subject to market risk, including possible loss of principal.

The fund(s) may have other share classes available that offer different investment minimums and fees. See the prospectus for details.

PERFORMANCE REVIEW

Earnings Strength, Bullish Sentiment Fueled Equity Rally
U.S. equities advanced in the quarter, continuing to ride the tailwinds of soft-landing sentiment in anticipation of interest rate cuts despite mixed economic signals throughout the period. While market performance broadened, large-caps fared best. Performance was mixed in January as expectations for aggressive interest rate cuts were tempered by strong economic data and comments from the U.S. Federal Reserve (Fed) indicating that the first of its expected round of interest rates cuts wasn't likely to come in March. Still, equities climbed through February, supported by some favorable corporate earnings reports and continued optimism about companies expected to benefit from demand for artificial intelligence (AI). Inflation and other economic data steadied in March, creating a more constructive backdrop for investors. While the Fed held rates at its March meeting, commentary continued to indicate multiple rate cuts could occur in 2024, potentially beginning as early as June.

Unfavorable Stock Choices in Health Care
Select names within the health care providers and services industry declined on guidance pressured by rising medical costs as well as disappointing rate increases negatively impacting Medicare Advantage plans, while certain pharmaceutical names continued to benefit from GLP-1 drug sales, strong drug pipelines, and acquisition agreements. Our choice of stocks within the sector hurt relative performance.

- UnitedHealth Group is a diversified U.S. managed care company. The firm has market-leading share in both private Medicare and Medicaid programs and is integrating vertically by acquiring providers and other services companies. Shares traded lower driven by a higher-than-expected medical loss ratio-the shares of premiums spent on health care-as many older Americans visited outpatient centers for procedures they put off during the pandemic. We continue to like UnitedHealth over the long term due to its strong Medicare and Medicaid businesses and other diversified business segments such as pharmacy, technology, and contract research organization.
- Revvity is a diagnostics and life sciences company focused on scientific innovation that spun off from PerkinElmer in 2023. Despite reporting above-consensus earnings in February, shares traded lower over the period amid industrywide headwinds due to weak demand from biotech and pharmaceutical companies. Revvity's global revenue profile could also pose a challenge due to foreign currency and idiosyncratic risks in some countries, including China. We continue to have a favorable view of Revvity for its exposure to the attractive medical technology industry and diversified end markets, and we took advantage of recent weakness to add to our position.

Utilities Detracted Due to Stock Selection
Optimism for possible interest rate cuts buoyed investor sentiment toward utilities, although company-specific factors, such as potential exposure to damages related to a Texas wildfire and robust guidance betting on clean energy demand growth, were performance drivers. Stock choices and an overweight allocation in the sector weighed on relative results.

- Xcel Energy operates utilities in the Midwest as well as in Texas and New Mexico. Shares of the company turned sharply lower during the quarter amid the outbreak of the largest recorded wildfire in Texas' history. In early March, the company acknowledged that one of its utility poles appeared to have caused the fire but also disputed claims that negligent maintenance or operation contributed to the ignition. We exited our position in the company during the period.

Information Technology Detracted Due to Stock Selection
Tech stocks' strength rolled on into the first quarter. Outsized gains in certain mega-caps continued, and software and services stocks generally reported solid performance. The ongoing swell in demand for generative artificial intelligence and its various applications persisted as a driving narrative for returns across the sector. Stock selection within the sector was unfavorable.

- Shares of NVIDIA, the leading designer of graphics processing units in its industry, continued to surge over the recent period, continuing a remarkable runup that began in early 2023, and we sold shares on strength. While our position in the company contributed to absolute returns, an underweight to the stock compared with the benchmark was a relative detractor. We believe NVIDIA is a high-quality company with increasing leverage to several up-and-coming secular growth markets. However, we are also mindful of diversifying our exposure to names levered to AI, and we are focused on identifying not just the primary beneficiaries from this technology's growth, but also the secondary beneficiaries like select names in software.

Consumer Discretionary Contributed Due to Stock Choices
Several apparel companies lagged, potentially due to dwindling pandemic-era savings as a result of rising interest rates, the resumption of student loan payments, and cuts in federal aid programs. On the other hand, select quick-service restaurants significantly benefited from revenue growth driven by increased sales volumes, store expansions, and robust digital business. Our choice of stocks in the sector added value, as did an underweight allocation.

- The portfolio does not hold a position in electric-car maker Tesla, and our underweight relative to the benchmark contributed to relative returns. Shares traded lower during the period over mounting concerns surrounding the company's CEO, as well increasing competition within the electric vehicle space from both established and emerging players. We maintained our lack of exposure to the company, informed by our concerns over Tesla's management team and its track record of execution, as well as the company's business model, which is relatively undiversified and does not fit our typical profile for investment.
- Shares of multinational hotel company Hilton traded higher on the heels of a strong earnings report. Revenue per available room, a key metric for the industry, grew more than expected, as did revenue from fees. Market participants also appeared to respond favorably to a strategic licensing agreement announced during the period, as well as a belief that the company would consider strategic acquisitive activity. We like Hilton for its asset-light model and believe that its low capital costs can be supportive of cash flow and growth over time. We also think the company's exposure to business travel will be a near-term tailwind amid the continued recovery in post-pandemic travel.

Stock Selection in Industrials and Business Services Added Value
The diversity of industries within the sector includes companies that were plagued by unique concerns, such as federal oversight

triggered by a mid-flight mishap and topline pressure from declining freight volumes and excess capacity, as well as businesses that benefited from reindustrialization trends, increasing networks, and dominant market share. Stock choices within the sector were beneficial during the period.

- Ingersoll Rand is a provider of a broad range of mission-critical air, fluid, energy, specialty vehicle, and medical technologies. Ingersoll Rand announced a well-received all-cash acquisition of an Italian air treatment design and production company, which Ingersoll Rand said will help the company achieve scale and add new capabilities in its air treatment business. A strong earnings report highlighted by strong organic revenue growth in its industrial technologies and services business further buoyed the share's price, and we pared our position on strength. We hold a favorable view of the company's continued efforts to achieve cost synergies and maintain its robust M&A pipeline.
- Shares of diversified industrial conglomerate Fortive outpaced sector peers. The company reported above-consensus revenue and earnings growth as well as strong margin expansion. Revenue growth in North America more than offset a slight decline in Asia, which assuaged market concerns over foreign exposure risk. We think Fortive is well positioned over the long term, with favorable leverage to an accelerating cyclical recovery, a strong management team, and a healthy balance sheet that could support opportunistic merger and acquisition activity.

PORTFOLIO POSITIONING AND ACTIVITY

As a result of our bottom-up stock selection process, sector positioning shifted within the equity portion of the portfolio. We bought shares in the health care, energy, and utilities sectors, and, conversely, we sold shares in the industrials and business services and information technology sectors.

Health Care

The health care sector continues to play a significant role in the portfolio, as we believe certain industries offer compelling, relatively stable growth potential at attractive valuations. We added positions in select sector names during the period.

- We initiated a position in Thermo Fisher Scientific, a leading provider of medical equipment and tools to help diagnose diseases and run clinical trials. We like the company for its excellent management team and attractive business mix, which has shifted toward higher-growth markets through both organic investment and acquisitions.
- We also initiated a position in Argenx, an antibody platform company. The company's FDA-approved therapeutic drug, Vyvgart (efgartigimod), is a leading treatment of generalized myasthenia gravis in adult patients. We believe there is a large commercial opportunity for the drug given its expansion into several additional indications, and we think the drug has the potential to not only be a first mover for the treatment of some conditions but also to have staying power as a best-in-class treatment over the long term.

Energy

Our exposure to the energy sector is concentrated in high-quality exploration and production names that demonstrate an ability to manage costs and effectively allocate capital. Within the sector, we seek companies that trade at attractive valuations and that offer strong balance sheets, high free cash flow, and effective management teams. We added to compelling opportunities within the sector.

- We increased our position in oil and natural gas producer Canadian Natural Resources. We remain positive on the company for its excellent operational execution, strong cash flow generation, and rock-solid balance sheet. Canadian Natural Resources also offers a deep inventory of oil sands and an attractive portfolio of assets in Canada and internationally, which we value.

Utilities

Within the utilities sector, we favor names with strong management teams, exposure to longer-term trends such as the shift toward renewable energy and electric vehicles, and that trade at a discount to their peers due to near-term uncertainty despite attractive long-term fundamentals. We added positions in select sector names during the period.

- We initiated a position in Essential Utilities, a holding company with two primary segments, a water utility and a regulated gas utility. The water utility serves a wide customer base across the East Coast, the Midwest, and Texas. The gas utility business, acquired in 2020, serves a smaller region focused in Pennsylvania, Kentucky, and West Virginia. We think both the company's water and gas business segments are above average within the industry and that present valuations represented a discount relative to peers.
- We initiated a position in NiSource, a gas and electric utility company with operations across six states. We like the company for its recent strong track record of execution and rate base growth. We think the company offers a potentially favorable risk/reward opportunity at current valuations and pays a solid dividend while also offering upside potential for earnings growth.

Industrials and Business Services

Within the industrials and business services sector, we seek to invest in companies that feature strong management teams with track records of superior capital allocation, solid business models, stable earnings growth, and high free cash flow yields. The sector has benefited from expectations for sustained economic activity and the potential for rate cuts in 2024. We bought shares at compelling valuations and also trimmed select positions on strength.

- We bought shares of Roper Technologies, an acquisitive, multi-industrial company with most of its business in software and about a quarter of its business in asset-light medical device and water meter companies. We like the company for its unique portfolio of assets, which have a leading share in a variety of niche end markets. We also think the company has a strong balance sheet and an operating model focused on generating steady free cash flow.
- GE Aerospace is the remaining company following a spinoff of the former industrial conglomerate into three more focused companies. Last year, the company completed the spinoff of its health care business into GE HealthCare. Shortly after the reporting period closed, the company also spun off its power and renewable energy business into GE Vernova. Shares of GE appreciated significantly since we incepted our holdings in the former industrial conglomerate in early 2019, and we exited our position on strength during the period.

Information Technology
The information technology sector plays a significant role within the portfolio. Within the sector, we have noteworthy positions in software and semiconductor companies that we believe have beneficial exposure to secular tailwinds. We added to our holdings in the sector.

- We exited our position in Analog Devices, a company that designs and manufactures integrated circuits and develops software that are used across a wide range of applications. Shares were volatile over the period but remained up meaningfully from recent lows, driven in part by the rising tide of interest in technology names levered to AI, and we eliminated our holdings on strength.

Fixed Income: Added to High-Quality High Yield
Our overall fixed income weight increased slightly. Our position in government debt, which is our largest position within fixed income, was unchanged over the period. Within government debt, we hold intermediate-term U.S. Treasuries, which we value for their ability to help provide ballast against equity market volatility and to generate income. Our position in bank loans, our second-largest fixed income position, was also relatively unchanged. Our exposure to high yield debt increased. Within high yield, we remain focused on identifying higher-quality issues and companies with attractive risk/return characteristics. Overall, our duration edged higher from last quarter.

MANAGER'S OUTLOOK

U.S. stock markets continued to surge during the recent quarter as major indexes rode a wave of positive sentiment to fresh highs, despite indications of sticky inflation and the potential for a delayed pivot in the Fed's monetary policy. Growth stocks outperformed value shares across all market capitalizations. Nearly all sectors within the S&P 500 Index advanced. The communication services sector fared best, lifted by gains for mega-cap names in entertainment and interactive media and services. The energy, information technology, financials, and industrials and business services sectors also outpaced the broader benchmark with double-digit gains. The real estate sector was a notable laggard and was the only sector to post negative returns during the period, albeit with only modest losses.
Entering 2024 in the wake of a resurgent year for equities, the macroeconomic consensus had shifted away from recession fears and toward expectations for a soft landing. In our view, stocks priced in this optimistic view leaving valuations elevated and their risk/reward profile less attractive, particularly for cyclical stocks. The positive sentiment that has driven this risk-on rally appears to have only risen during the first quarter. Fueled by expectations for the Federal Reserve to cut rates and momentum trading in names both directly and indirectly associated with the potential impact of artificial intelligence adoption, we think market expectations have become dislocated from underlying fundamentals. While we do still see attractive opportunities in less cyclical areas of the market, we have continued to position the portfolio with a modest effective underweight to equities against this backdrop of stretched valuations and pervasive optimism.
At the end of 2022, when market expectations were heavily tilted toward a Fed-induced recession, we positioned the portfolio with an overweight to equities, reflecting our view that a severe recession was unlikely. In recent months, as sentiment has further fueled a risk-on rally that brought major indexes to record highs and diminished the potential upside in stocks, we have taken a more cautious approach. We believe taking a contrarian position, when it is supported by our rigorous fundamental analysis, adds value over time. We remain focused on corporate fundamentals and identifying opportunities to invest that we think can add value over the long term, while also paring positions where valuations appear extended. As a result, our effective exposure to equities remained moderately underweight over the period. As always, we remain committed to finding the best risk-adjusted opportunities across the asset class spectrum to help balance our goals of preserving invested capital and generating equity-like returns over the long term with less risk than the broader equity market.

QUARTERLY ATTRIBUTION

SECTOR ATTRIBUTION DATA VS. S&P 500 INDEX (EQUITY ONLY)

(3 months ended March 31, 2024)



	Total	Con-sumer Disc	Indust & Bus Svcs	Energy	Real Es-tate	Materi-als	Con-sumer Staples	Comm Svcs	Finan-cials	Info Tech	Utilities	Health Care
Over/Underweight	0.00%	-3.48%	7.06%	0.68%	-1.84%	-0.02%	-5.97%	-2.50%	-2.28%	-5.45%	5.93%	7.87%
Fund Performance	8.71	9.33	13.54	17.18	-14.20	14.15	-11.96	16.79	9.70	10.61	-0.28	2.21
Index Performance	10.56	4.98	10.84	13.69	-0.55	8.95	7.52	15.82	12.46	12.74	4.57	8.85
Value Add - Group Weight	-0.10	0.18	0.02	0.05	0.23	0.03	0.16	-0.11	-0.05	-0.13	-0.35	-0.13
Value Add - Stock Selection	-1.74	0.33	0.44	0.15	-0.07	0.05	-0.10	0.06	-0.28	-0.50	-0.41	-1.41
Total Contribution	-1.85	0.51	0.46	0.20	0.16	0.08	0.06	-0.05	-0.33	-0.63	-0.76	-1.54

Past performance is not a reliable indicator of future performance. Numbers may not total due to rounding; all numbers are percentages. Analysis represents the equity only performance of the portfolio as calculated by the FactSet attribution model and is exclusive of non-equity positions and equity options. Returns will not match official T. Rowe Price performance because FactSet uses different exchange rate sources and does not capture intra-day trading. Performance for each security is obtained in the local currency and, if necessary, is converted to USD using an exchange rate determined by an independent third party. Figures are shown with gross dividends reinvested. Sources: Financial data and analytics provider FactSet. Copyright 2024 FactSet. All Rights Reserved. MSCI/S&P GICS Sectors; Analysis by T. Rowe Price. T. Rowe Price uses the current MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting. Figures are shown gross of fees. Returns would be lower as a result of the deduction of such fees. Performance returns are in USD.

TOP 5 ABSOLUTE CONTRIBUTORS — EQUITY ONLY

(3 months ended March 31, 2024)

Issuer	% of Fund
Microsoft	5.0%
Amazon.com	2.4
Fortive	2.3
NVIDIA	1.9
Meta Platforms	1.2

TOP 5 ABSOLUTE DETRACTORS — EQUITY ONLY

(3 months ended March 31, 2024)

Issuer	% of Fund
Apple	1.5%
Biogen	0.6
Aurora Innovation	0.4
XCEL Energy	0.0
Mobileye Global	0.0

12-MONTH ATTRIBUTION

SECTOR ATTRIBUTION DATA VS. S&P 500 INDEX (EQUITY ONLY)

(12 months ended March 31, 2024)



	Total	Consumer Staples	Indust & Bus Svcs	Energy	Consumer Disc	Real Estate	Materials	Financials	Comm Svcs	Info Tech	Utilities	Health Care
Over/Underweight	0.00%	-5.97%	7.06%	0.68%	-3.48%	-1.84%	-0.02%	-2.28%	-2.50%	-5.45%	5.93%	7.87%
Fund Performance	26.35	-16.31	34.81	32.07	36.74	8.51	33.21	36.86	63.92	43.35	-8.74	4.56
Index Performance	29.88	7.19	26.46	17.67	28.73	10.32	17.57	33.55	49.76	46.14	0.42	16.09
Value Add - Group Weight	-1.91	1.41	-0.08	0.35	0.13	0.50	0.15	-0.03	-0.59	-0.51	-1.86	-1.37
Value Add - Stock Selection	-1.63	-0.13	1.20	0.43	0.54	-0.05	0.20	0.37	0.58	-0.65	-1.02	-3.08
Total Contribution	-3.53	1.28	1.12	0.77	0.67	0.45	0.35	0.33	-0.01	-1.17	-2.88	-4.45

Past performance is not a reliable indicator of future performance. Numbers may not total due to rounding; all numbers are percentages. Analysis represents the equity only performance of the portfolio as calculated by the FactSet attribution model and is exclusive of non-equity positions and equity options. Returns will not match official T. Rowe Price performance because FactSet uses different exchange rate sources and does not capture intra-day trading. Performance for each security is obtained in the local currency and, if necessary, is converted to USD using an exchange rate determined by an independent third party. Figures are shown with gross dividends reinvested. Sources: Financial data and analytics provider FactSet. Copyright 2024 FactSet. All Rights Reserved. MSCI/S&P GICS Sectors; Analysis by T. Rowe Price. T. Rowe Price uses the current MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting. Figures are shown gross of fees. Returns would be lower as a result of the deduction of such fees. Performance returns are in USD.

TOP 5 ABSOLUTE CONTRIBUTORS — EQUITY ONLY

(12 months ended March 31, 2024)

Issuer	% of Fund
Microsoft	5.0%
Alphabet	2.8
Amazon.com	2.4
NVIDIA	1.9
Meta Platforms	1.2

TOP 5 ABSOLUTE DETRACTORS — EQUITY ONLY

(12 months ended March 31, 2024)

Issuer	% of Fund
Revvity	1.9%
Ameren	1.0
Biogen	0.6
Thermo Fisher Scientific	0.5
XCEL Energy	0.0

HISTORICAL ASSET ALLOCATION



ASSET CLASS RANGES: 12/31/1999 – 3/31/2024

% of Total	Common Stock	Convertibles	Bond	Reserves
Current	62.3%	0.3%	32.6%	5.0%
Average	62.9	4.4	20.7	11.9
Maximum	72.2	19.2	32.6	23.5
Minimum	51.9	0.1	5.0	1.9

PORTFOLIO POSITIONING

SECTOR DIVERSIFICATION – CHANGES OVER TIME — EQUITY ONLY



LARGEST PURCHASES

Issuer	Sector	% of Fund Current Quarter 3/31/24	% of Fund Prior Quarter 12/31/23
Canadian Natural Resources		2.0%	1.1%
Thermo Fisher Scientific (N)		0.5	0.0
Lam Research (N)		0.5	0.0
Essential Utilities (N)		0.5	0.0
Roper Technologies		1.5	1.2
KLA (N)		0.4	0.0
Marsh & McLennan		0.9	0.5
NiSource		0.4	0.0
McDonald's (N)		0.3	0.0
Argenx (N)		0.3	0.0

LARGEST SALES

Issuer	Sector	% of Fund Current Quarter 3/31/24	% of Fund Prior Quarter 12/31/23
XCEL Energy (E)		0.0%	1.2%
Ingersoll-Rand		0.7	1.4
Analog Devices (NE)		0.0	0.0
Yum! Brands		1.8	2.3
NVIDIA		1.9	1.5
Keurig Dr Pepper (E)		0.0	0.5
AMETEK (N)		0.4	0.0
KKR		0.6	0.8
Stryker (E)		0.0	0.3
Goldman Sachs		0.5	0.8

(N) New Position
(E) Eliminated
(NE) New Position Eliminated
A purchase or sale that occurred as a result of a corporate action where the Portfolio Manager had no discretion, if any, will not be displayed.
Securities are shown in order by their total net cost and proceed values. Net is defined as total cost of purchases less total proceeds of sales.

HOLDINGS

TOP 10 ISSUERS

Issuer	Industry	% of Fund	% of S&P 500 Index
Microsoft	Software	5.0%	7.1%
Alphabet	Interactive Media & Services	2.8	3.7
UnitedHealth Group	Health Care Providers & Svcs	2.4	1.0
Amazon.com	Broadline Retail	2.4	3.7
Fortive	Machinery	2.3	0.1
Canadian Natural Resources	Oil, Gas & Consumable Fuels	2.0	0.0
Becton, Dickinson & Company	Health Care Equip & Supplies	2.0	0.2
Waste Connections	Commercial Services & Supplies	2.0	0.0
Revvity	Life Sciences Tools & Services	1.9	0.0
NVIDIA	Semicons & Semicon Equip	1.9	5.1

TOP 5 OVER/UNDERWEIGHT POSITIONS VS. S&P 500 INDEX

Issuer	Industry	% of Fund	% of S&P 500 Index	Over/Underweight
Fortive	Machinery	2.3%	0.1%	2.2%
Canadian Natural Resources	Oil, Gas & Consumable Fuels	2.0	0.0	2.0
Waste Connections	Commercial Services & Supplies	2.0	0.0	2.0
Revvity	Life Sciences Tools & Services	1.9	0.0	1.9
Becton, Dickinson & Company	Health Care Equip & Supplies	2.0	0.2	1.8
Apple	Tech. Hard., Stor. & Periph.	1.5	5.6	-4.2
NVIDIA	Semicons & Semicon Equip	1.9	5.1	-3.2
Microsoft	Software	5.0	7.1	-2.1
Berkshire Hathaway CL A	Financial Services	0.0	1.7	-1.7
Amazon.com	Broadline Retail	2.4	3.7	-1.4

PORTFOLIO MANAGEMENT



Portfolio Manager:
David Giroux

Managed Fund Since:
2006

Joined Firm:
1998

Additional Disclosures

Consider the investment objectives, risks, and charges and expenses carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, call 1-800-638-7780 or visit troweprice.com. Read it carefully.

The S&P 500 Index is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates (“SPDJI”) and has been licensed for use by T. Rowe Price. Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC, a division of S&P Global (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). This product is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates, or none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P 500 Index.
Unless otherwise noted, index returns are shown with gross dividends reinvested.
Fund Assets, holdings-based analytics (excluding portfolio turnover), and portfolio attribution are calculated using T. Rowe Price’s internal Investment Book of Records (IBOR). Due to timing and accounting methodology differences, IBOR data may differ from the Accounting Book of Records (ABOR) data provided by the Fund’s accountant.
The manager’s views and portfolio holdings are historical and subject to change. This material should not be deemed a recommendation to buy or sell any of the securities mentioned. The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for the Fund and no assumptions should be made that the securities identified and discussed were or will be profitable.
T. Rowe Price uses the current MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting. Effective March 17, 2023, the GICS structure changed. Sector/industry diversification data prior to that date have not been restated. Historical attribution data has been restated.
The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc, ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by T. Rowe Price. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any or such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.
Equities include common stocks as well as convertible securities.
Diversification exhibits may not add to 100% due to exclusion or inclusion of cash.
Certain numbers in this report may not equal stated totals due to rounding. Unless otherwise stated, data is as of the report date.
Unless indicated otherwise the source of all data is T. Rowe Price.
Closed to new investors. Open to subsequent investments.
This material has been prepared for informational purposes only. The views and opinions stated in this commentary are those of the portfolio managers listed as of the date indicated. These views and opinions are subject to change based on market or other conditions and may differ from those of other T. Rowe Price associates. Actual market and investment results may differ materially from expectations.

T. Rowe Price Investment Services, Inc., Distributor.
202404-3481745